Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Revoten
- Development stage
- Unknown
- Lead developer
- PharmaSGP
- Administration
- Oral
01
Overview
Revoten is an over-the-counter homeopathic medicine developed and marketed by PharmaSGP for the treatment of weak connective tissue and its visible manifestations, such as cellulite, stretch marks, spider veins, and sagging skin. Formulated as oral tablets, Revoten contains a dual active complex consisting of Acidum silicicum (silicic acid) Trit. D4 and Calcium carbonicum Hahnemanni (Hahnemann's calcium carbonate) Trit. D4. These homeopathic ingredients are traditionally used to strengthen connective tissue from within, improving skin elasticity and firmness without known side effects or drug interactions.
- Brand names
- Revoten
- Other names
- Acidum silicicum + Calcium carbonicumAcidum silicicum + Calcium carbonicum Hahnemanni
Beyond the preview
Go deeper on Revoten.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Revoten.